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Introduction
There has been much interest in carotid artery wall thick-
ening as a marker of atherosclerosis, both by ultrasound
and more recently by magnetic resonance (MR). Ultra-
sound measurements are limited by the presumption that
the vessel is uniform. MR does not have this limitation.
Rosiglitazone (RSG) is a nuclear PPAR-gamma agonist
and has important effects in diabetes control which has
led to its widespread use as a complement to existing dia-
betes drugs. It is known to lead to minor fluid retention in
some patients, and recent reports suggest that it may be
associated with an increased risk of ischemic cardiovascu-
lar events. However, this effect is controversial and may
not be seen with all glitazones.
Purpose
We conducted a CMR study of the use of rosiglitazone in
diabetic patients to determine its effect on atherosclerotic
burden.
Methods
We enrolled 48 patients with type 2 diabetes mellitus.
There were 41 male and 7 female subjects, 80% were talk-
ing statins/fibrates. Subjects were eligible if they had doc-
umented carotid atheroma on screening carotid
ultrasonography and then underwent carotid CMR at
baseline, six months, and after 1 year. Patients were ran-
domised to RSG 4 mg od (uptitrated to RSG 4 mg bd at 12
wks) or placebo in addition to their background anti-dia-
betic therapy in a double-blind manner. Carotid CMR
study was performed using a 1.5 T Siemens Sonata scan-
ner and phased-array surface carotid coils. We acquired a
3D stack of high-resolution fast spin echo images centred
on the carotid bifurcation. Maximal coverage was 56 mm
(28 mm either side of the bifurcation) with a slice thick-
ness of 2 mm. Where possible, bilateral carotid evaluation
was undertaken. Using dedicated semi-automated soft-
ware (Atheroma Tools, Cardiovascular Imaging Solutions,
London) we traced the internal and external carotid artery
surfaces for each slice and hence measured the luminal
area and the wall area. Using the 3D model of the carotid
artery generated by this analysis, we measured the lumen
volume and total vessel volume to generate a total wall
volume, a measure of atherosclerotic burden. Data was
analysed using analysis of covariance.
Results
There was no significant difference in carotid atheroma
between subjects treated with Rosiglitazone or placebo
after 1 year. (Table 1).
Conclusion
Rosiglitazone has no effect on the development of carotid
atheroma in patients with type 2 diabetes over one year.
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Carotid Plaque RSG Placebo
Total Wall Volume (mm3) (N = 25) (N = 29)
N 21 26
Baseline (mean ± SD) 1354 ± 532 1146 ± 550
End of Treatment (mean ± SD) 1348 ± 531 1134 ± 523
Change from Baseline (mean ± SD) -5.7 ± 79.4 -12.1 ± 105
Model Adjusted Change from Baseline (mean ± SE) 12.7 ± 22.8 -2.9 ± 20.9
Difference from Placebo: mean (95% CI2) 15.7 (-39.5, 70.9) -
P-value 0.57 -Page 2 of 2
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